Sarfaraz K. Niazi, PhD, dived into the benefits of the FDA's recently announced Biosimilar Regulatory Science Program, which is expected to help progress biosimilar development and simplify evaluations for interchangeability status.
Recently, the FDA unveiled a significant effort to streamline the approval of biosimilars. For the first time, the new website highlights how the development of biosimilar products can be advanced and how the interchangeable product evaluation can be simplified and made more practical.
The FDA has made a significant shift in its priorities, as explained below:
I am looking forward to significant changes in the Biologics Price Competition and Innovation Act, but what the FDA has disclosed today should incentivize developers to present novel ideas that will reduce the cost and time to market—an essential paradigm shift needed to make biosimilars affordable. Great News!
Author Bio
Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical Sciences at the College of Pharmacy at the University of Illinois at Chicago and a patent law practitioner. Additionally, he is the founder and executive chairman at Pharmaceutical Scientist, Inc, the executive chairman of Karyo Biologics, and the founder of Adello Biologics, which was acquired by Kashiv Biosciences in 2019. Niazi also serves on the advisory board for The Center for Biosimilars®.
Link to Dr. Niazi’s last column: https://www.centerforbiosimilars.com/view/biorationality-a-dr-sarfaraz-niazi-column-the-ema-declares-biosimilars-interchangeable
References
[1]McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: Past, present, and future considerations. Transfusion. 2008;48:1754-1762. doi:10.1111/j.1537-2995.2008.01749.x
[2]Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant. 2005;20S:33-40. doi:10.1093/ndt/gfh1072
[3]Niazi SK. Biosimilars: A futuristic fast-to-market advice to developers. 2021:149-155. doi:10.1080/14712598.2022.2020241
[4] Niazi SK. Molecular biosimilarity-an AI-driven paradigm shift. Int J Mol Sci. 2022;23(18):10690. doi:10.3390/ijms231810690
[5] Niazi S. Scientific rationale for waiving clinical efficacy testing of biosimilars. Drug Des Devel Ther. 2022;16:2803-2815. doi: 10.2147/DDDT.S378813
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.